Patient and Caregiver Involvement With Prior Authorization and Care Delivery and Delays

Posted July 21, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JULY 23, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.24901?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072326

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this survey study, direct patient or caregiver prior authorization (PA) engagement was associated with adverse outcomes, including delays, not receiving care as prescribed, and negative perception of PA. This is consistent with prior research describing patient-reported delays and suboptimal care. This study may be used to shape future research and intervention development to help patients, caregivers, clinicians, and advocates navigate PA-related administrative burden.

Corresponding Author: To contact the corresponding author, Bridgette Thom, PhD, email bridgette.thom@unc.edu.

(doi:10.1001/jamanetworkopen.2026.24901)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prevalence and Associated Factors of Intentional Outdoor Tanning Among US Adults

Posted July 20, 2026 by Jim Michalski

JAMA Dermatology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JULY 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2026.2450?guestAccessKey=50f461db-4c55-467a-aee7-d1f2de6baf59&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072226

About The Study: This cross-sectional study found that the highest prevalence of intentional outdoor tanning occurs among U.S. women who are younger, non-Hispanic white, and physically active and report heavy and/or binge drinking. Those who engage in intentional outdoor tanning are more likely to experience sunburn, increasing their skin cancer risk. These findings can inform future strategies to address intentional outdoor tanning as part of larger efforts to reduce skin cancer risk.

Corresponding Author: To contact the corresponding author, Dawn M. Holman, MPH, email dholman@cdc.gov.

(doi:10.1001/jamadermatol.2026.2450)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Drinking Water Contaminant Exposures and Risk of Uterine Cancer

Posted July 20, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JULY 22, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.24391?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of female California educators, associations between drinking water trihalomethanes and uterine cancer overall and with endometrioid tumors specifically were consistent with findings from the only prior study, conducted in the midwestern U.S. Further investigation of drinking water contaminants as modifiable risk factors for this common gynecologic cancer is warranted.

Corresponding Author: To contact the corresponding author, Rena R. Jones, PhD, MS, email rena.jones@nih.gov.

(doi:10.1001/jamanetworkopen.2026.24391)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Screening Eligibility and Survival Among Patients With Lung Cancer in Korea

Posted July 17, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JULY 21, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.24143?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of Korean patients with lung cancer, international screening guidelines excluded 64.6% of patients, a substantial proportion of whom had no smoking history. Ineligible patients had lower mortality risk than screening-eligible patients. These findings suggest that population-specific strategies are needed to improve early detection among individuals not captured by current screening criteria.

Corresponding Author: To contact the corresponding author, Yeon Wook Kim, MD, PhD, email kimyw@snu.ac.kr.

(doi:10.1001/jamanetworkopen.2026.24143)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Racial Differences in Secondary Treatment Pathways and Survival in Localized Prostate Cancer

Posted July 17, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JULY 21, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.24155?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of men treated for localized prostate cancer, treatment receipt after primary definitive treatment was similar by race. No mortality differences were found among those who received secondary treatment; however, observed mortality disparities among those who did not receive secondary treatment raise concerns about potential health care inequities.

Corresponding Author: To contact the corresponding author, Jessica Acolin, PhD, email jyacolin@uw.edu.

(doi:10.1001/jamanetworkopen.2026.24155)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Road Traffic Noise, Noise Difference Between Residential Facades, and Risk of Parkinson Disease

Posted July 16, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JULY 20, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.2262?guestAccessKey=2f0d4c50-6325-4d79-92d9-107a7123088f&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026

About The Study: Results of this cohort study show that long-term exposure to road traffic noise was associated with higher Parkinson disease risk. Having a quiet facade mitigated this association. These findings suggest noise as a novel risk factor for Parkinson disease and support mitigation strategies ensuring a quiet residential side.

Corresponding Author: To contact the corresponding author, Mette Sorensen, PhD, email mettes@cancer.dk.

(doi:10.1001/jamaneurol.2026.2262)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons

Posted July 16, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JULY 20, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2760?guestAccessKey=c016cf02-707b-4125-8157-fc7f04a8e4c5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026

About The Study: In this randomized clinical trial, clesrovimab, a long-acting monoclonal antibody, was well tolerated in infants at increased risk for severe respiratory syncytial virus (RSV) disease through 2 RSV seasons. These findings support the use of clesrovimab in children who remain at risk for severe RSV disease in their second RSV season.

Corresponding Author: To contact the corresponding author, Anushua Sinha, MD, MPH, email anushua.sinha@merck.com.

(doi:10.1001/jamapediatrics.2026.2760)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Spousal Dementia Exposure and Risk of Dementia

Posted July 16, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JULY 20, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.24175?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of married individuals in Taiwan, spouses of individuals with dementia had a higher risk of dementia than unexposed spouses. The association varied across family and socioeconomic contexts, highlighting the relevance of household context in dementia risk assessment.

Corresponding Author: To contact the corresponding author, Chi-Shin Wu, MD, PhD, email chishinwu@nhri.edu.tw.

(doi:10.1001/jamanetworkopen.2026.24175)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prevalence of LDL-C Above 2026 Dyslipidemia Guideline Goals Among US Adults

Posted July 16, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JULY 20, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10529?guestAccessKey=3a4d75e7-c16f-4755-a5be-0069506fa852&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026

About The Study: In this nationally representative analysis, applying low-density lipoprotein cholesterol (LDL-C) goals from the 2026 American College of Cardiology/American Heart Association dyslipidemia guideline to 2021 to 2023 U.S. population data revealed substantial gaps in LDL-C control, with an increasing gradient across primary prevention categories and high proportions among adults with established atherosclerotic cardiovascular disease. These gaps were accompanied by substantial underuse of lipid-lowering therapy. These findings provide a contemporary population-level benchmark for the updated guideline framework.

Corresponding Author: To contact the corresponding author, Shady Abohashem, MD, MPH, sabohashem@mgh.harvard.edu.

(doi:10.1001/jama.2026.10529)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cardiovascular Risk Reclassification With the 2026 Dyslipidemia Guideline

Posted July 16, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JULY 20, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.11152?guestAccessKey=b8c84aa0-8620-40cb-8bbe-4a84ce4a3343&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026

About The Study: Adoption of the 2026 American College of Cardiology/American Heart Association/Multisociety Dyslipidemia Guideline and Predicting Risk of Cardiovascular Disease EVENTs (PREVENT)-ASCVD (atherosclerotic cardiovascular disease) reclassified approximately one-quarter of adults, with two-thirds of those reassigned to lower-risk categories and one-third reassigned to higher-risk categories. Males, non-Hispanic Black individuals, and currently smoking individuals were most frequently reassigned downward, whereas females and individuals with diabetes were more often reassigned upward.

Corresponding Author: To contact the corresponding author, Allison W. Peng, MD, email apeng4@jh.edu.

(doi:10.1001/jama.2026.11152)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy

Posted July 16, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JULY 20, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.11246?guestAccessKey=e817de9c-4743-4aa3-b048-3f4c62734a1c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026

About The Study: The 2026 American College of Cardiology/American Heart Association/multisociety guideline on the management of dyslipidemia issued new recommendations on estimating atherosclerotic cardiovascular disease risk and on populations eligible for statins for primary prevention. This study found that the guideline substantially expands the U.S. population recommended for primary prevention statin therapy, predominantly in lower-risk individuals.

Corresponding Author: To contact the corresponding author, Timothy S. Anderson, M.D., M.A.S., email tsander@pitt.edu.

(doi:10.1001/jama.2026.11246)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

What Is Cyclosporiasis?

Posted July 20, 2026 by Hannah Alani

JAMA

EMBARGOED FOR RELEASE: 11:05 A.M. ET, TUESDAY, JULY 21, 2026

Media advisory: The full Patient Page is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.14866?guestAccessKey=7dfcee3c-df5d-40a4-a004-eba81bd22663&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072126

About The Patient Page: A mid-June cyclosporiasis outbreak has affected thousands of people. As of July 17, based on data from the U.S. Centers for Disease Control and Prevention (CDC), there were 1,645 confirmed cases of cyclosporiasis and more than 5,100 additional suspected cases in 34 states.

On July 16, the CDC announced that an outbreak of cyclosporiasis in 5 states was linked to shredded iceberg lettuce; the CDC is currently also investigating several other outbreaks of cyclosporiasis in the U.S. that may have a different source.

This JAMA Patient Page outlines how people become infected with cyclosporiasis, which is an infection of the small bowel caused by the parasite Cyclospora cayetanensis.

Authors detail common symptoms, symptom onset, diagnosis, treatment, and tips for prevention, such as washing raw produce, removing the outer layer of produce (such as with a head of lettuce) and washing packaged produce (such as salad mixes), even if labeled prewashed.

Interviews: Co-author Kathleen A. Linder, MD, is affiliated with the Division of Infectious Disease, Department of Internal Medicine, Michigan Medicine, Ann Arbor, and the Infectious Diseases Section, Ann Arbor VA Healthcare System, Ann Arbor, Michigan. Contact Chris Arbino (christopher.arbino@va.gov) to schedule interviews.

(doi:10.1001/jama.2026.14866)

Editor’s Note: Please see the Patient Page for additional information, including author affiliations and conflict of interest disclosures.

Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand

Posted July 15, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JULY 17, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.2207?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071726

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: The findings of this study show that, after the end of the semaglutide and tirzepatide shortages, compounding facilities have continued to manufacture glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with added ingredients. Compounded GLP-1 RA sourcing is diverse but includes facilities without licenses to perform sterile compounding or that have been subject to recent disciplinary action, posing clinical and regulatory challenges.

Corresponding Author: To contact the corresponding author, Michael J. DiStefano, PhD, email michael.j.distefano@cuanschutz.edu.

(doi:10.1001/jamahealthforum.2026.2207)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Problematic Social Media Use and ADHD Symptoms in Adolescents

Posted July 15, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, JULY 17, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.23748?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This cohort study of U.S. youths found that year-to-year elevations in self-reported problematic social media use were directly associated with attention-deficit/hyperactivity disorder (ADHD) symptoms during mid-adolescence, particularly among males; reverse associations of ADHD symptoms with later problematic social media use were small in magnitude and sporadic. Screening for hard-to-control social media use, time spent on social media, and attention to sex-specific patterns may be warranted, although the population-based associations may be small.

Corresponding Author: To contact the corresponding author, Jason M. Nagata, MD, MSc, email jason.nagata@ucsf.edu.

(doi:10.1001/jamanetworkopen.2026.23748)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Availability of Naloxone in Retail Pharmacies Following Introduction of Over-the-Counter Status

Posted July 15, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, JULY 17, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.23617?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study of pharmacies across the U.S., same-day naloxone availability and price remained uneven following over-the counter (OTC) approval. As an initial national evaluation of same-day naloxone availability and price after OTC approval, the findings showed differences in implementation across pharmacy types and community demographic features. Although enactment of the OTC policy was necessary, its intended benefits were not realized equally in practice. Expanding pharmacist education and targeting support for independent and medical-affiliated pharmacies may help improve naloxone access, especially in rural and underserved areas.

Corresponding Author: To contact the corresponding author, Lori Ann Eldridge, PhD, email eldridgel21@ecu.edu.

(doi:10.1001/jamanetworkopen.2026.23617)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Commercial Price Variation for Common Cardiovascular Services Across 4 Major US Insurers

Posted July 14, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JULY 16, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.23326?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071626

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study of commercial insurance payments for cardiology services, there was substantial variation across both insurers and states, particularly in facility fees. These findings reveal the influence of payer contracting strategies and market dynamics and underscore the need for greater transparency and regulatory oversight to promote efficient health care spending.

Corresponding Author: To contact the corresponding author, Christopher Whaley, PhD, email christopher_whaley@brown.edu.

(doi:10.1001/jamanetworkopen.2026.23326)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cancer Type–Specific Contributions to the Reduction in Cancer Mortality Gap Between Black Individuals and White Individuals

Posted July 14, 2026 by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 16, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.2400?guestAccessKey=0f2a0ca5-9ce6-4bae-af86-7756e0db64be&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071626

About The Study: In this cross-sectional temporal analysis, the marked reductions in excess mortality indicate meaningful progress achieved for several major cancer types through population-wide cancer control efforts. Persistent or worsening disparities in breast cancer and uterine corpus cancer and substantial residual disparities in prostate cancer highlight priorities for equitable interventions. These findings may guide more targeted and efficient cancer prevention and control strategies to further accelerate progress.

Corresponding Author: To contact the corresponding author, Chenxi Jiang, MPH, email chenxi.jiang@cancer.org.

(doi:10.1001/jamaoncol.2026.2400)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Modifiable Risk Factors and Attributable Ischemic Heart Disease Mortality in US States, 1990-2023

Posted July 13, 2026 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JULY 15, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2026.2435?guestAccessKey=013f94b4-b91d-4e60-8ce5-d0bce752e318&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071526

About The Study: Modifiable risk factors are a major cause of ischemic heart disease in the U.S., with increasing contributions attributable to high body mass index and high fasting plasma glucose; addressing barriers to reducing risk exposure is essential to lessen ischemic heart disease mortality.

Corresponding Author: To contact the corresponding author, Gregory A. Roth, MD, email rothg@uw.edu.

(doi:10.1001/jamacardio.2026.2435)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Lobbying Trends in Psychiatry and Psychology

Posted July 13, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JULY 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1921?guestAccessKey=eaa80f3e-a44d-4193-89c3-bd3806e59f6c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071526

About The Study: This economic evaluation characterizes U.S. lobbying spending in the mental health field between 2014 and 2024.

Corresponding Author: To contact the corresponding author, Anmoldeep Singh, BA, email anmoldeep-singh@ou.edu.

(10.1001/jamapsychiatry.2026.1921)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Ceperognastat in Early Symptomatic Alzheimer Disease

Posted July 10, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:05 A.M. ET, MONDAY, JULY 13, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being published to coincide with the Alzheimer’s Association International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.12768?guestAccessKey=c0bca90d-cce8-4e0b-abc8-d83fddff8aa9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071326

About The Study: Ceperognastat, a novel, orally available, small-molecule inhibitor of O-linked N-acetylglucosaminidase, did not slow disease progression of early symptomatic Alzheimer disease.

Corresponding Author: To contact the corresponding author, Adam S. Fleisher, MD, email afleisher@lilly.com.

(doi:10.1001/jama.2026.12768)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease

Posted July 10, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:05 A.M. ET, MONDAY, JULY 13, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being published to coincide with the Alzheimer’s Association International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.13116?guestAccessKey=d6cf3764-1b31-4899-8ad1-e25ecd5e7e8e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071326

About The Study: In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.

Corresponding Author: To contact the corresponding author, Ganna Blazhenets, PhD, email ganna.blazhenets@ucsf.edu.

(doi:10.1001/jama.2026.13116)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Colorectal Cancer Treatment Delay Thresholds and Metastasis Risk

Posted July 10, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JULY 14, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.23057?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study, colorectal cancer treatment delays were associated with higher, pathway-specific metastasis risk. These findings support pathway-tailored benchmarks for treatment initiation and highlight the importance of integrated care in reducing delays and improving timely, equitable, cost-effective colorectal cancer care.

Corresponding Author: To contact the corresponding author, Chi M. Nguyen, PhD, email cmnguyen@iu.edu.

(doi:10.1001/jamanetworkopen.2026.23057)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment

Posted July 13, 2026 by Hannah Alani

JAMA

EMBARGOED FOR RELEASE: 12:00 A.M. ET, WEDNESDAY, JULY 15, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the Alzheimer’s Association International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.12556?guestAccessKey=a8d06b6f-944f-4862-b6cf-7e8ccfa9cc89&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071426

About The Study: A study in JAMA presented Wednesday, July 15, at the annual Alzheimer’s Association International Conference reports that a blood test measuring phosphorylated tau 217 (P‑tau217) in plasma can help estimate an individual’s risk of developing cognitive impairment over the following 2, 5, and 10 years.

Across six cohorts, higher p-tau217 levels were consistently associated with increased risk of progression to cognitive impairment in cognitively unimpaired older adults, and the association remained significant after adjustment for amyloid PET.

The findings support P‑tau217 as a marker linked to amyloid and tau-related disease processes. If ongoing secondary prevention trials demonstrate that early intervention can delay or prevent cognitive decline, blood‑based biomarkers like P‑tau217 could help identify individuals most likely to benefit, authors note.

However, current Alzheimer’s Association clinical practice guidelines recommend against testing cognitively unimpaired older adults outside research studies or clinical trials.

Authors emphasize that the risk estimates are based on selected research cohorts, with greater confidence in 5‑year than 10‑year projections, and that current models do not fully account for vascular comorbidities or competing risk of death; additionally, P-tau217 may not fully reflect non-Alzheimer contributors to cognitive impairment, such as vascular or other neurodegenerative processes.

Author Interviews: Contributing author Rachel F. Buckley, PhD, will present findings from the paper Wednesday, July 15, at the AAIC meeting in London. To request an interview with Prof Buckley or corresponding author Reisa Sperling, MD, email Noah Brown of the Mass General Brigham Media Relations office at nbrown9@mgb.org.

To request an interview with contributing author and biostatistician Ron Brookmeyer, PhD, MS, email Carla Denly of the Fielding school of Public Health office at UCLA at cdenly@ph.ucla.edu.

(doi:10.1001/jama.2026.12556)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Neurological Manifestations of Hantavirus Infection

Posted July 10, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, JULY 14, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.2437?guestAccessKey=6b4938c5-e42a-4330-887d-0e98abf941d5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071426

About The Study: Neurological manifestations of hantavirus infection are uncommon but can be severe. Prospective studies and experimental models are needed to better characterize these manifestations, understand pathophysiology, identify therapeutic targets, and develop guidelines for management.

Corresponding Author: To contact the corresponding author, Avindra Nath, MD, email natha@ninds.nih.gov.

(doi:10.1001/jamaneurol.2026.2437)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Age, Multidomain Lifestyle Intervention, and White Matter Integrity

Posted July 9, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 3 A.M. ET, MONDAY, JULY 13, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Alzheimer’s Association International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.20353?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071326

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this secondary imaging analysis of a randomized clinical trial, free water was the cerebrovascular magnetic resonance imaging (MRI) marker most responsive to lifestyle intervention in adults 60 to 70 years of age, showing attenuated small-vessel disease–related injury. Findings suggested greater microvascular benefit when intensive lifestyle intervention is implemented earlier in late life.

Corresponding Author: To contact the corresponding author, Pauline Maillard, PhD, email pmaillard@health.ucdavis.edu.

(doi:10.1001/jamanetworkopen.2026.20353)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Medically Assisted Reproduction and Hormone-Related Cancers

Posted July 9, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JULY 13, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.22832?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071326

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of medically assisted reproduction and cancer using a target trial emulation design, although associations between medically assisted reproduction and some hormone-related cancers were observed, the estimated difference in the number of expected cancers was small and may be explained by unmeasured confounding and detection bias.

Corresponding Author: To contact the corresponding author, Adrian Raymond Walker, PhD, email adrian.walker@unsw.edu.au.

(doi:10.1001/jamanetworkopen.2026.22832)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Vitamin K Prophylaxis in Newborns and Bleeding in Infancy

Posted July 9, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JULY 13 , 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2606?guestAccessKey=8c13bf9c-6c31-48e2-b99b-f64c368d394a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071326

About The Study: This cohort study shows that the number of infants in Sweden who do not receive intramuscular vitamin K administration at birth to prevent bleeding episodes continues to be low but is increasing, and these infants have a significantly higher associated risk of bleeding episodes, including intracranial hemorrhages. These findings suggest the importance of intramuscular vitamin K administration in the newborn period to prevent bleeding episodes and the need for continued education of parents and caregivers on its significance.

Corresponding Author: To contact the corresponding author, Eleni Simatou, MD, email eleni.simatou@ki.se.

(doi:10.1001/jamapediatrics.2026.2606)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Trends in Dementia Prevalence Across Latin America and the Caribbean

Posted July 9, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 6 A.M. (ET), MONDAY, JULY 13, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Alzheimer’s Association International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.2305?guestAccessKey=8ed664f9-22ca-4163-966b-4da752d1e00b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071326

About The Study: The findings of this study suggest that dementia prevalence is rising across several Latin American settings, contrasting with declining trends in high-income countries. These findings, while specific to 5 studied sites, highlight the growing and uneven burden of dementia in the region and underscore the need for strengthened surveillance, risk reduction strategies, and investment in dementia care infrastructure.

Corresponding Author: To contact the corresponding author, Jorge J. Llibre-Guerra, MD, MSc, email jllibre-guerra@wustl.edu.

(doi:10.1001/jamaneurol.2026.2305)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Hantavirus on a Nature Cruise and the Risk of a Pandemic

Posted July 8, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 9, 2026

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.3600?guestAccessKey=076278ea-597e-4c49-abc0-d6187f64c591&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070926

About The Article: This Viewpoint discusses the alarm surrounding the hantavirus cases first reported in May 2026 and burgeoning threats, such as Ebola virus.

Corresponding Author: To contact the corresponding author, Daniel J. Morgan, MD, MS, email dmorgan@som.umaryland.edu.

(doi:10.1001/jamainternmed.2026.3600)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Patient Engagement With Open Notes Following the 21st Century Cures Act

Posted July 8, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JULY 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.2097?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071026

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: The 21st Century Cures Act mandated that patients have immediate access to clinical notes and other health information (i.e., open notes). At a large, integrated health system, open notes engagement increased rapidly following implementation and plateaued at 55% within 2 months, with substantial sociodemographic disparities in engagement. These disparities may be attributed to the digital divide. Language may be another barrier, as notes are not routinely translated despite multilingual portal interfaces.

Corresponding Author: To contact the corresponding author, Ishani Ganguli, MD, MPH, email iganguli@bwh.harvard.edu.

(doi:10.1001/jamahealthforum.2026.2097)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Measles-Containing Vaccine Use for Children Ages 12 to 47 Months, 2015 to 2025

Posted July 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, JULY 10, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.22734?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this study, 15% of King County, Washington children received measles, mumps, rubella, and varicella (MMRV) as their first measles-containing vaccine and varicella-containing vaccine dose, a proportion that remained stable over time. Compared with other children in this analysis, more children who received MMRV were from minoritized racial and ethnic groups; received a catch-up dose; were Vaccines for Children-eligible; and were vaccinated at safety-net clinics. This population might be at risk of not receiving recommended vaccines if options become limited.

Corresponding Author: To contact the corresponding author, Eric J. Chow, MD, MS, MPH, email erchow@kingcounty.gov.

(doi:10.1001/jamanetworkopen.2026.22734)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer

Posted July 8, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 3:30 A.M. ET, SUNDAY, JULY 12, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the International Society on Thrombosis and Haemostasis 2026 Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10676?guestAccessKey=c9dab843-adf3-4827-b344-9c429039f331&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071226

About The Study: In patients with cancer and suspected pulmonary embolism, a diagnostic strategy using the YEARS diagnostic algorithm was as safe as using computed tomographic pulmonary angiography (CTPA) only, thus, obviating the need to perform CTPA in 22% of patients.

Corresponding Author: To contact the corresponding author, Menno V. Huisman, MD, PhD, email m.v.huisman@LUMC.nl.

(doi:10.1001/jama.2026.10676)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease

Posted July 8, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 12:15 P.M. ET, SUNDAY, JULY 12, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Alzheimer’s Association International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.13058?guestAccessKey=db15c1f6-7f67-4b2c-8c6a-1094739bd236&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071226

About The Study: In this case report, areas of extensive amyloid clearance after amyloid-targeting therapy were associated with less downstream neuropathologic change. In addition, amyloid clearance appears to preferentially occur in the gyral crests. Future studies should evaluate the differential mechanisms involved in amyloid clearance from superficial and deep cortical layers and in gyri and sulci because extensive amyloid clearance may be necessary to achieve downstream neuropathologic benefit after removal of amyloid.

Corresponding Author: To contact the corresponding author, Edward B. Lee, MD, PhD, email edward.lee@pennmedicine.upenn.edu.

(doi:10.1001/jama.2026.13058)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Sustained Availability of Dedicated High School Health Courses and Adolescent Substance Use

Posted July 7, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JULY 9, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.22676?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070926

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of California public high schools, sustained availability of a dedicated health course was associated with modestly lower prevalence in several common forms of adolescent substance use. These findings suggest that sustained, dedicated health coursework may be a scalable component of school-based substance use prevention.

Corresponding Author: To contact the corresponding author, Brennan Davis, PhD, email bdavis39@calpoly.edu.

(doi:10.1001/jamanetworkopen.2026.22676)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Olfactory Impairment and Depression

Posted July 7, 2026 by Jim Michalski

JAMA Otolaryngology–Head & Neck Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 9, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2026.1758?guestAccessKey=8cf2e4f9-9c78-4913-b23e-7482d56750f1&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070926

About The Study: This systematic review and meta-analysis found that subjective olfactory impairment is consistently associated with depression, while objective impairment shows associations mainly in aging and anosmic subgroups, suggesting partly distinct underlying mechanisms.

Corresponding Author: To contact the corresponding author, Henry Bode, MD, email henry.bode@ki.se.

(doi:10.1001/jamaoto.2026.1758)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Formulary-Related Insurance Denials of Single-Source Branded Drugs in the US

Posted July 7, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JULY 9, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8702?guestAccessKey=b444c622-c50e-4c99-b93b-4c5c7541b7c6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070926

About The Study: Among this large, diverse sample of individuals in the United States, formulary rejections were frequent and often resulted in delayed or absent treatment, highlighting trade-offs between cost and access to medicines.

Corresponding Author: To contact the corresponding author, Joseph F. Levy, PhD, email jlevy@jhu.edu.

(doi:10.1001/jama.2026.8702)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

The Reinforcement Effect of Social Media Likes in Depression

Posted July 6, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JULY 8, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1430?guestAccessKey=7884e28f-537e-4885-922a-a7d110aad531&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070826

About The Study: In this study, depressive psychopathology was associated with a greater tendency to be reinforced by a type of social reward on Twitter, in contrast to typical laboratory-based findings of blunted reinforcement learning in depression. These findings suggest potential mechanisms linking social media use to worse mental health or vice versa, and emphasize the importance of studying real-world behavior.

Corresponding Author: To contact the corresponding author, Dan-Mircea Mirea, PhD, email dmirea@princeton.edu.

(10.1001/jamapsychiatry.2026.1430)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Deaths Caused by Law Enforcement in the US

Posted July 6, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JULY 8, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9981?guestAccessKey=f78741cc-7f1e-4b12-af99-418a7cc52906&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070826

About The Study: From 2003 to 2024, annual deaths caused by law enforcement and reported in death certificate data increased from 363 to 809 among adults and from 8 to 37 among children. Non-Hispanic Black males had the highest mortality rates each year, indicating persistent racial disparities, even in adolescence. Firearms caused more than 87% of deaths.

Corresponding Author: To contact the corresponding author, Caroline Raymond-King, MD, PhD, email c.king@yale.edu.

(doi:10.1001/jama.2026.9981)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Birth Weight Percentiles and Infant and Child Growth Dynamics

Posted July 6, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JULY 8, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.22218?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of 38,535 singletons, birth weight decile was associated with early-life growth patterns. Birth weight decile group may help identify high-risk children missed by conventional thresholds, although the benefit of analysis using decile group over traditional groups remains modest.

Corresponding Author: To contact the corresponding author, Ahmed Elhakeem, PhD, email a.elhakeem@bristol.ac.uk.

(doi:10.1001/jamanetworkopen.2026.22218)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Opioid Use and Pain Resolution for Acute Pain Among Opioid-Naive Patients

Posted July 2, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JULY 7, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.21875?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of opioid-naive patients with acute pain, opioid use was generally low dose and of short duration, although some patients reported prolonged opioid use; most reported achieving pain resolution within 3 weeks, with longer times for surgical and low back pain. The findings suggest current guidelines for multimodal treatment and for short-duration opioid prescriptions if needed will serve many but not all patients, and treatment should be tailored to address individual patients’ needs.

Corresponding Author: To contact the corresponding author, Molly Moore Jeffery, PhD, MPP, email jeffery.molly@mayo.edu.

(doi:10.1001/jamanetworkopen.2026.21875)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Perceived Risk of Fentanyl Use Among US Adolescents

Posted July 2, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JULY 7, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.22039?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this survey study, an appreciable portion of adolescents—particularly the younger ones—were not aware of the dangers of fentanyl use. Clinicians, parents, schools, and public education programs all have important roles in communicating the potentially life-threatening risks of fentanyl misuse to adolescents.

Corresponding Author: To contact the corresponding author, Richard Miech, PhD, email ramiech@umich.edu.

(doi:10.1001/jamanetworkopen.2026.22039)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Primary Care–Initiated Continuous Glucose Monitoring in Adults With Insulin-Treated Diabetes

Posted July 1, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JULY 6, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.21713?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070626

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of adults with insulin-treated diabetes, initiation of continuous glucose monitoring (CGM) by primary care clinicians was associated with clinically meaningful improvements in HbA1c and significant reductions in recurrent hospitalizations and emergency department visits. These findings support expanding CGM implementation in primary care settings as a scalable strategy to improve diabetes outcomes and reduce acute care utilization, particularly in underserved populations.

Corresponding Author: To contact the corresponding author, Jovan Milosavljevic, MD, MS, email jmilosavlj@montefiore.org.

(doi:10.1001/jamanetworkopen.2026.21713)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Online Prescribing of GLP-1 Receptor Agonists

Posted July 1, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JULY 6, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9131?guestAccessKey=fa92b2cf-8029-44c4-a5ea-da5b3d264967&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070626

About The Study: This secret shopper study found that online glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription vendors often did not require clinician interaction, relying primarily on patient-reported questionnaires that may not capture important clinical and social history. Several findings suggest limited oversight: multiple GLP-1 RA prescriptions from the same clinicians, prescriptions issued despite missing required photos, and prescriptions issued within 5 minutes or less.

Corresponding Author: To contact the corresponding author, Reshma Ramachandran, MD, MPP, MHS, email reshma.ramachandran@yale.edu.

(doi:10.1001/jama.2026.9131)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Urbanicity, Neighborhood Conditions, and Dementia Mortality

Posted June 30, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JULY 2, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.21153?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study, dementia mortality risk was greatest in mid-urbanicity and lower in dense urban cores and rural areas, and this gradient was largely attenuated by neighborhood conditions. These findings suggest that targeted improvements in modifiable neighborhood conditions may substantially reduce dementia mortality and advance equity, particularly in vulnerable communities.

Corresponding Author: To contact the corresponding author, Shujuan Chen, MS, email sc2343@cam.ac.uk.

(doi:10.1001/jamanetworkopen.2026.21153)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Friend Caregivers Among Older Adults

Posted June 30, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JULY 2, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.21697?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study of Medicare beneficiaries age 65 and older, friend caregivers represented a specialized segment of the unpaid caregiving workforce, particularly for older adults lacking family resources. Understanding how friends provide care can help health care professionals better recognize them as an integral part of the caregiving network.

Corresponding Author: To contact the corresponding author, Yee To Ng, PhD, email yeetong@umich.edu.

(doi:10.1001/jamanetworkopen.2026.21697)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Football-Specific On-Pitch Concussion Assessment Protocol— International Consensus Recommendations

Posted June 29, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JULY 1, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.2298?guestAccessKey=a81b391a-5dc1-4ffb-a227-105669ece242&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070126

About The Study: A new international consensus has established FOCUS as a football-specific on-pitch concussion assessment protocol, addressing the unique demands of rapid decision-making during match play.

Developed as a rapid, evidence-informed framework, FOCUS consists of 45 assessment items across 11 domains, including player medical history, injury mechanism, visible signs, consciousness, cervical spine assessment, symptoms, orientation, balance, proprioception, oculomotor function, and activity-based evaluation.

The protocol prioritizes identifying clinical signs and symptoms requiring immediate player removal, with structured yet practical assessment steps feasible for completion in under 3 minutes during a game. While FOCUS provides an important tool to standardize concussion management for football globally, further research is needed to evaluate its effectiveness in real-world settings and across diverse resource environments.

About the Authors: This Special Communication is coauthored by 18 authors from 15 institutions across 11 countries: Bolivia (TUMI Institute), Brazil (Brazilian Football Federation), Burkina Faso (Université Lédéa Bernard Ouédraogo (ULBO)-Public University – Ouahigouya), Ireland (Cork University Hospital), Japan (Toho University Ohashi Medical Center, Department of Neurosurgery), Mauritania (centre hospitalier des spécialités (CHS) Nouakchott), Netherlands (Koninklijke Nederlandse Voetbalbond (KNVB)- Royal Dutch Football Association, Zeist), New Zealand (Axis Sports Medicine Clinic, Auckland), Switzerland (Federation Internationale de Football Association; Union of European Football Association), United Kingdom (Queen’s University Belfast; University of Birmingham), and United States (United States Soccer Federation; Mass General Brigham Inc; Major League Soccer).

Corresponding Author Kerry Peek, PhD, of the Federal Federation Internationale de Football Association (FIFA) can be reached at kerry.peek@fifa.org.

(doi:10.1001/jamaneurol.2026.2298)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adolescent Peers’ Diagnoses and Genetic Predispositions and Subsequent Risk of Mental Disorders

Posted June 29, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JULY 1, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1752?guestAccessKey=e2f95300-58f2-4177-9492-f0dd17fe748b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070126

About The Study: The findings of this cohort study suggest that peer environments, particularly in upper secondary school settings, are associated with mental health trajectories. More research is needed to elucidate the mechanisms underlying these findings.

Corresponding Author: To contact the corresponding author, Jussi Alho, PhD, email jussi.alho@helsinki.fi.

(10.1001/jamapsychiatry.2026.1752)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Barriers to Nutrition Security in the US

Posted June 26, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.20264?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=063026

Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders

Posted June 26, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19985?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=063026

Validity of Area-Based Social Risk Indices Used at Higher-Level Geographies and Clinic Locations

Posted June 26, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.20504?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=063026

Use of Social Media for Health Information Among US Adults

Posted June 26, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 30, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8682?guestAccessKey=1cba3ba2-3afb-4761-8832-95c44e107519&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=063026

About The Study: In this nationally representative survey, the majority of U.S. adults using social media reported some engagement with health-related information on these platforms. Social media has become a major venue for health information, yet confidence in its accuracy remains limited. This disconnect may reflect features of platforms optimized for engagement over accuracy. Importantly, more than 20% of people made health decisions based on social media, despite almost 80% reporting distrust, suggesting exposure may influence behavior, even when reliability is questioned.

Corresponding Author: To contact the corresponding author, Rohan Khera, MD, MS, email rohan.khera@yale.edu.

(doi:10.1001/jama.2026.8682)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

HPV–Related Cancer in People With HIV and Solid Organ Transplant Recipients

Posted June 26, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 30, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.20512?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=063026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this case-control study of immunosuppressed populations, human papillomavirus (HPV)-related cancer odds were increased among both people with HIV and solid organ transplant recipients, with larger magnitudes of association observed in people with HIV; variation was observed by immune status, transplant characteristics, and sociodemographic factors. These findings highlight the need for enhanced prevention, including HPV vaccination, screening, and optimized immunosuppressive regimens.

Corresponding Author: To contact the corresponding author, Eva Meglic, MSc, email eva.meglic@ki.se.

(doi:10.1001/jamanetworkopen.2026.20512)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Asynchronous Electronic Screening for Unhealthy Alcohol Use Among Veterans in Primary Care

Posted June 25, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1517?guestAccessKey=b4e1959b-f890-46f8-ab3a-0dfd6970e169&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062926

Evaluation of Alternative Smoking Duration Criteria for Lung Cancer Screening

Posted June 25, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.2732?guestAccessKey=da4ff61f-aa51-4395-b635-4d90b25bc096&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062926

Mindfulness-Based Group Medical Visits for Persons With Chronic Low Back Pain

Posted June 25, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 29, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.2186?guestAccessKey=ee174564-1aee-4df1-a7dd-19a8443be70c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062926

About The Study: In this randomized clinical trial, a telehealth-delivered mindfulness group medical visit program for persons with chronic low back pain (CLBP) resulted in significant improvements in pain intensity and interference compared with usual care; however, these changes did not meet the prespecified mean 1-point minimal clinically important difference between groups. The program incorporated primary care clinicians, was accessible, and is potentially scalable as a nonpharmacologic treatment for CLBP.

Corresponding Author: To contact the corresponding author, Natalia E. Morone, MD, MS, email natalia.morone@bmc.org.

(doi:10.1001/jamainternmed.2026.2186)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or ADHD Among Sibling-Matched Cohorts

Posted June 25, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 29, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.2215?guestAccessKey=41c1ba2f-5a8b-4b37-a8b9-10f0073bb1d8&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062926

About The Study: In this population-based cohort study, a sibling-matched analysis found no evidence of an association between prenatal paracetamol (acetaminophen) exposure and the risk of autism spectrum disorder or attention-deficit/hyperactivity disorder (ADHD) in offspring. The positive signals observed in conventional studies are likely attributable to residual familial confounding. These findings provide important reassurance regarding the safety of indicated paracetamol use during pregnancy.

Corresponding Authors: To contact the corresponding authors, email Eric Yuk Fai Wan, PhD, (yfwan@hku.hk) and Ian Chi Kei Wong, PhD, (i.wong1@aston.ac.uk).

(doi:10.1001/jamainternmed.2026.2215)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

GLP-1 Prescriptions for Weight Loss by Differences in Insurance Plan Coverage

Posted June 24, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JUNE 26, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1838?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=062626

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: This cross-sectional study found a substantial increase in glucagon-like peptide-1 (GLP-1) per-patient days supplied in employer plans over the study period (2021-2024), with higher growth in plans that covered GLP-1s for weight loss. With increases in utilization, the estimate of differential per member per month cost for GLP-1 coverage is increasing over time and could signal higher financial burden on patients and payers in the future, though some of the added drug cost (yet unquantified) is likely offset by lower medical spending.

Corresponding Author: To contact the corresponding author, Mahnum Shahzad, PhD, email mahnum_shahzad@g.harvard.edu.

(doi:10.1001/jamahealthforum.2026.1838)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Smell and Taste Disturbances Among GLP-1 RA Users

Posted June 23, 2026 by Jim Michalski

JAMA Otolaryngology–Head & Neck Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 25, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2026.1498?guestAccessKey=3b532415-ee88-4cca-b197-829aae61730b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062526

About The Study: The findings of this study suggest that glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy is associated with a higher risk of smell and taste disturbance, highlighting the need for closer monitoring and greater public health awareness. Future research is required to validate these findings and to further explore the mechanisms underlying this association.

Corresponding Author: To contact the corresponding author, Nir Zontag, BSc, email nir.zontag@mail.huji.ac.il.

(doi:10.1001/jamaoto.2026.1498)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Diet Quality and Dementia Risk in Older Adults With Alzheimer Pathology

Posted June 23, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JUNE 25, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.20254?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This cohort study of older adults found that adherence to a dietary pattern with lower inflammatory potential was associated with lower dementia risk among individuals with Alzheimer disease pathology and broader neurobiological risk. These findings reinforce the importance of targeted dietary dementia prevention strategies not only for the general population but also for individuals already at elevated risk.

Corresponding Author: To contact the corresponding author, Anja Mrhar, MSc, email anja.mrhar@ki.se.

(doi:10.1001/jamanetworkopen.2026.20254)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Use and Misuse of GLP-1 Receptor Agonists Among People With Eating Disorders

Posted June 22, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 24, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1716?guestAccessKey=b318a96e-d60a-4ba7-a59e-51eda11620e3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062426

About The Study: This cross-sectional study found that glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and misuse were common in a targeted sample of people with eating disorders. The prevalence of lifetime GLP-1 RA use was higher among people with eating disorders than the 15% observed in the general adult population. People with eating disorders are a clinically diverse population who may be consuming GLP-1 RAs in contraindicated ways to maintain eating disorder psychopathology through rapid restriction and weight loss.

Corresponding Author: To contact the corresponding author, Nicholas C. Peiper, PhD, MPH, email nicholas.peiper@louisville.edu.

(10.1001/jamapsychiatry.2026.1716)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Comprehensive Smoke-Free Laws and Cardiovascular Disease Mortality in US Counties

Posted June 22, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 12:45 P.M. ET, WEDNESDAY, JUNE 24, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Society for Epidemiologic Research Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.21170?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this comparative effectiveness research study of county-level smoke-free laws, comprehensive smoke-free laws were associated with sustained reductions in cardiovascular disease mortality. However, the magnitude of the associations varied across demographic groups, suggesting that additional strategies addressing disparities in tobacco exposure may be needed to achieve improvement in cardiovascular outcomes across all subpopulations.

Corresponding Author: To contact the corresponding author, Chuyue Wu, MD, MPH, email chuyuewu@g.ucla.edu.

(doi:10.1001/jamanetworkopen.2026.21170)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adolescent Suicidality After State-Level Total Abortion Bans

Posted June 22, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 24, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.21632?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study of high school students, implementation of total abortion bans was associated with increased suicidal ideation among female students, with similar but less precise estimates observed for suicide attempts. These findings suggest that the policies in these states may adversely influence female adolescents’ mental health and underscore the importance of accessible suicide prevention and mental health services in affected states.

Corresponding Author: To contact the corresponding author, Wendy R. Sheldon, PhD, MPH, MSW, email wsheldon@vergeresearch.org.

(doi:10.1001/jamanetworkopen.2026.21632)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Self-Directed vs Clinician-Delivered Cognitive Behavioral Therapy for Chronic Pain

Posted June 22, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 24, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7861?guestAccessKey=36fd489f-57b4-4218-a3d2-d319ffe83e35&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062426

About The Study: Self-directed cognitive behavioral therapy for chronic pain (CBT-CP) was associated with modest improvements in pain interference at 4 months that were sustained to 12 months, small to moderate improvements in all secondary outcomes at 4 months, and higher session-completion rates, relative to clinician-delivered CBT-CP. Scalable, convenient self-directed CBT may be an effective alternative to clinician-delivered CBT that could increase uptake of CBT-CP.

Corresponding Author: To contact the corresponding author, Alicia Heapy, PhD, email alicia.heapy@va.gov.

(doi:10.1001/jama.2026.7861)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Maternal Cardiovascular Health During Pregnancy and Offspring Developmental Delay

Posted June 18, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 23, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18804?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062326

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of mother and offspring pairs in Japan, better maternal cardiovascular health during pregnancy was associated with a lower risk of offspring developmental delay at age 4 years.

Corresponding Author: To contact the corresponding author, Mami Ishikuro, PhD, email mami.ishikuro.e5@tohoku.ac.jp.

(doi:10.1001/jamanetworkopen.2026.18804)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design

Posted June 18, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11:10 A.M. ET, TUESDAY, JUNE 23, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.25152?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062326

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this study, receipt of 2025-2026 COVID-19 vaccination was associated with additional protection beyond existing immunity in adults against medically attended COVID-19, including emergency department/urgent care encounters and hospitalizations, compared with no receipt of a 2025-2026 vaccine dose. These findings suggest that adults can reduce their likelihood of severe COVID-19–associated outcomes by obtaining a 2025-2026 COVID-19 vaccination.

Corresponding Author: To contact the corresponding author, Ruth Link-Gelles, PhD, MPH, email hzt7@cdc.gov.

(doi:10.1001/jamanetworkopen.2026.25152)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Abortion Bans and Pregnancy-Related Care Across Physician Specialties

Posted June 17, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19644?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this qualitative study of the consequences of abortion bans across multiple medical specialties, abortion bans were associated with disrupted clinical care far beyond what is traditionally categorized as abortion, with treatment delays that endanger patients, undermined patient autonomy and physician-patient trust, and with new gatekeeping roles for physicians. These restrictions shifted medical decision-making from clinical judgment and patient values toward legal risk mitigation, with potential long-term consequences including exacerbation of health care inequities and compromised ability to provide safe and effective care for pregnant patients.

Corresponding Author: To contact the corresponding author, Sophia Landay, MD, email slanday@bidmc.harvard.edu.

(doi:10.1001/jamanetworkopen.2026.19644)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management

Posted June 17, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2248?guestAccessKey=cbe93f86-f6f2-40da-87ce-c910b069a258&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062226

About The Study: The findings of this systematic review and network meta-analysis suggest that combining lifestyle treatment with obesity management medications was associated with the greatest short-term (typically 6 to 12 months) weight reduction in adolescents with obesity. Health behavior and lifestyle treatment remained an indispensable component of any effective weight management, delivering meaningful weight loss and healthier body composition on its own. Combined with lifestyle treatment, pharmacotherapy was a key component, not solely an adjunct, associated with the greatest body mass index (BMI) and BMI z score improvements, and long-term sustainability and safety were monitored.

Corresponding Author: To contact the corresponding author, Bjorn T. Tam, PhD, email bjorntam@hkbu.edu.hk.

(doi:10.1001/jamapediatrics.2026.2248)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Mental Health Treatment Disparities Among Transition-Age Youth With Suicidal Thoughts and Behaviors

Posted June 17, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2261?guestAccessKey=1619d29f-e9bd-4443-b0a8-df53cce63279&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062226

About The Study: This nationally representative study showed that 1 in 8 transition-age youth (TAY) had suicidal thoughts and behaviors (STB), yet less than half of those with STB had any mental health care. Asian, Black, and Latine TAY experienced substantial access disparities, with treatment rates 14 to 21 percentage points lower than white peers. Despite all TAY having STB in the subsample in this study, the large service access differences suggest that structural barriers, rather than clinical appropriateness or patient preference alone, drive these inequities.

Corresponding Author: To contact the corresponding author, Michael William Flores, PhD, MPH, email mwflores@cha.harvard.edu.

(doi:10.1001/jamapediatrics.2026.2261)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

The Texas Abortion Ban and Maternal Mental Health

Posted June 16, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JUNE 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19396?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this repeated cross-sectional study, the implementation of an abortion ban in Texas was associated with a worsening of maternal mental health among reproductive-age mothers relative to mothers in states without such bans. These results underscore the association of abortion restrictions with maternal mental health and highlight the need to strengthen support in the post-Dobbs policy environment.

Corresponding Author: To contact the corresponding author, Alyssa L. Burnett, MPH, email alyssa_burnett@hphci.harvard.edu.

(doi:10.1001/jamanetworkopen.2026.19396)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Changes in Medication Use After Medicare Part D Annual Out-of-Pocket Spending Caps

Posted June 16, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11:15 A.M. (ET), THURSDAY, JUNE 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1545?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061826

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: This study found that medication use increased after implementation of Medicare annual out-of-pocket cost caps, particularly among the highest-cost medications. These results suggest that the policy substantially improved patient access to high-cost medications for Medicare-insured patients.

Corresponding Author: To contact the corresponding author, Christopher L. Cai, MD, email chrislcai@gmail.com.

(doi:10.1001/jamahealthforum.2026.1545)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prone Positioning in Infants With Acute Bronchiolitis

Posted June 15, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9:30 A.M. ET, WEDNESDAY, JUNE 17, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the International Congress of European Society of Paediatric and Neonatal Intensive Care.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.11078?guestAccessKey=931bd4b5-dc5d-4ea2-a0e1-7b7f0d12b9a4&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061726

About The Study: Prone positioning in infants with moderate to severe bronchiolitis receiving high-flow nasal cannula support did not significantly reduce escalation of care. However, the wide 95% confidence interval around the observed odds ratio suggests that this study was not definitive and further research is warranted.

Corresponding Author: To contact the corresponding author, Florent Baudin, MD, PhD, email florent.baudin@chu-lyon.fr.

(doi:10.1001/jama.2026.11078)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season

Posted June 15, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 17, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18581?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This surveillance study found that while antigenically drifted viruses predominated and caused substantial morbidity and mortality, influenza vaccines were associated with a reduced risk of influenza among those who were vaccinated, and recommended antivirals remained effective.

Corresponding Author: To contact the corresponding author, Eduardo Azziz-Baumgartner, MD, email Eha9@cdc.gov.

(doi:10.1001/jamanetworkopen.2026.18581)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Gestational Exposure to 10 Classes of Priority Chemicals and Birth Outcomes in the ECHO Cohort

Posted June 15, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 17, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18883?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This large cohort study of diverse U.S. pregnancies found widespread exposure to 10 classes of environmental chemicals, many of which were associated with differences in gestational age at birth or lower birth weight-for-gestational age z scores. These findings indicate that reducing gestational exposure to chemicals, particularly phthalates or alternative plasticizers and polycyclic aromatic hydrocarbons, could promote healthy deliveries and better child outcomes.

Corresponding Authors: To contact the corresponding authors, email Jessie P. Buckley, PhD, MPH, (Jessie.Buckley@unc.edu) and Tracey J. Woodruff, PhD, MPH, (traceyw@stanford.edu).

(doi:10.1001/jamanetworkopen.2026.18883)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Three-Year Contraceptive Failure Rates During the HER Salt Lake Contraceptive Initiative

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17273?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18677?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Days at Home After Hip Fracture Among Older Adults With and Without Dementia

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18658?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Short-Acting Opioid Dose and Patient-Directed Discharge in Hospitalized Patients With Opioid Use Disorder

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18698?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Sociodemographic, Health Care, and Clinical Factors Associated With Metabolic Bariatric Surgery Uptake Among US Adults With Obesity

Posted June 12, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 16, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18686?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061626

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of individuals with an initial obesity diagnosis, uptake of metabolic bariatric surgery was patterned by demographic, clinical, and health care factors. This finding suggests substantial opportunity to improve access to metabolic bariatric surgery through targeted policies and interventions.

Corresponding Author: To contact the corresponding author, Rafeya V. Raquib, MS, email rraquib@bu.edu.

(doi:10.1001/jamanetworkopen.2026.18686)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans

Posted June 11, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1929?guestAccessKey=d13423b6-0f97-447a-a381-df38354146d7&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this cohort study, receipt of the 2024-2025 COVID-19 vaccine was associated with reduced risk of COVID-19–associated major adverse cardiovascular event (MACE), with reductions most prominent in those 75 years or older and those with comorbidities. While the reduction in COVID-19–associated MACE was modest, the substantially larger reduction in all-cause MACE suggests that the vaccine’s protective association extends to the hidden burden of undetected SARS-CoV-2 and its sequelae.

Corresponding Author: To contact the corresponding author, Ziyad Al-Aly, MD, email ziyad.alaly@va.gov.

(doi:10.1001/jamainternmed.2026.1929)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults

Posted June 11, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1936?guestAccessKey=e928166b-0148-4f49-a5c9-7e1e089110b2&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this test-negative case-control study, 2024-2025 COVID-19 vaccination was associated with reduced likelihood of medically attended COVID-19–associated outcomes among immunocompetent and immunocompromised adults, highlighting the importance of adults receiving recommended COVID-19 vaccinations.

Corresponding Author: To contact the corresponding author, Ryan E. Wiegand, PhD, email rwiegand@cdc.gov.

(doi:10.1001/jamainternmed.2026.1936)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Parent and Child Media Use During Family Meals in US Households

Posted June 11, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2182?guestAccessKey=a766de15-cfec-4035-9fd4-2066f37fd4f2&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this study, differences were observed in parent and child mealtime media use patterns among racial and ethnic groups. Specifically, Black parental race was positively associated with paired use; Asian parental race was associated with more individual use. These findings may reflect broader cultural differences in family communication, parental intervention styles, and the role of media in parent-child interaction.

Corresponding Author: To contact the corresponding author, Matthew A. Lapierre, PhD, email mlapierre@arizona.edu.

(doi:10.1001/jamapediatrics.2026.2182)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Acoustic Analysis of Primary Care Patient–Clinician Conversations to Screen for Cognitive Impairment

Posted June 11, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1868?guestAccessKey=bb6fdcfa-b129-402f-93c4-2e3d5bc49b0c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this diagnostic study, machine learning models trained on acoustic features from brief clinical conversations identified cognitive impairment with high accuracy. These findings support the feasibility of passive, speech-based screening during routine primary care.

Corresponding Author: To contact the corresponding author, Joseph T. Colonel, PhD, email joseph.colonel@mssm.edu.

(doi:10.1001/jamaneurol.2026.1868)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Emerging Patterns in Dietary Supplement Use Among US Adults, 1999-2023

Posted June 11, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19291?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this repeated cross-sectional analysis of NHANES 1999 to 2023, supplement use among U.S. adults increased over time, with diversification beyond multivitamin-multiminerals toward products marketed for immune, anti-inflammatory, gut, skin, or joint health. A substantial increase was observed in older adults. Ongoing monitoring of supplement use trends is needed to understand evolving public health implications.

Corresponding Author: To contact the corresponding author, Chun Sing Lam, PhD, email lamc3@mskcc.org.

(doi:10.1001/jamanetworkopen.2026.19291)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

COVID-19 Vaccine Effectiveness Among Older Adults

Posted June 11, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19040?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: Vaccines administered in autumn and winter 2025 to 2026 showed approximately 55% effectiveness against symptomatic disease among older adults within 2 months of vaccination. The low uptake of vaccines, which showed substantial short-term effectiveness, suggests missed opportunities for preventing symptomatic COVID-19 among unvaccinated vulnerable groups.

Corresponding Author: To contact the corresponding author, Charlotte Laniece Delaunay, PhD, email c.laniece@epiconcept.fr.

(doi:10.1001/jamanetworkopen.2026.19040)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

An AI-Based OCT System to Detect Diabetic Macular Edema

Posted June 10, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7025?guestAccessKey=d9385aaa-55ec-45a2-8d72-0918a28925e3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: Compared with standard practice, incorporation of the AI-based optical coherence tomography (AI-OCT) system as a secondary screening tool was noninferior with respect to false-positive referral rates and was associated with a substantial reduction in potentially unnecessary diabetic macular edema referrals without compromising sensitivity.

Corresponding Authors: To contact the corresponding authors, email Simon K. H. Szeto, MBChB (simonkhszeto@cuhk.edu.hk) and Carol Y. Cheung, PhD (carolcheung@cuhk.edu.hk).

(doi:10.1001/jama.2026.7025)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes

Posted June 10, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8492?guestAccessKey=39974582-15cb-42b1-9c06-9adef66b64fe&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: Among adults with prediabetes at baseline, lifestyle intervention, but not metformin, was associated with a lower burden of multimorbidity. Lifestyle programs may persistently lower the development of chronic conditions.

Corresponding Author: To contact the corresponding author, Marcel E. Salive, MD, email dppmail@bsc.gwu.edu.

(doi:10.1001/jama.2026.8492)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Health Equity After a Colorectal Cancer Screening Program

Posted June 10, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JUNE 12, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1520?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061226

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: In this cross-sectional study, following the implementation of an organized population screening program, colorectal cancer screening participation increased and socioeconomic disparities narrowed over time. Overall uptake in Hong Kong remains low, and some disparities persist in younger age groups (age 50-59 years), single households, individuals with a primary and secondary school education, lower-income groups, and public housing residents. Efforts to increase participation are needed in certain groups to ensure health equity.

Corresponding Author: To contact the corresponding author, Jianchao Quan, MD, email jquan@hku.hk.

(doi:10.1001/jamahealthforum.2026.1520)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Internet Searches for Leucovorin, Folate, and Acetaminophen After a White House Autism Announcement

Posted June 9, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JUNE 11, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17910?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: During a press conference on September 22, 2025, President Trump and top health officials endorsed use of leucovorin, a generic drug formulated from folinic acid, for treatment of autism, and urged against acetaminophen use during pregnancy, stating concerns about its risk for development of autism in children. The White House announcement was associated with large increases in internet searches over the subsequent 2 weeks, including more than 1 million additional searches for leucovorin; nearly 81,000 additional purchasing interest searches for leucovorin, folinic acid, or folate; and more than 4 million additional searches for acetaminophen with pregnancy or autism.

Corresponding Author: To contact the corresponding author, Joseph S. Ross, MD, MHS, email joseph.ross@yale.edu.

(doi:10.1001/jamanetworkopen.2026.17910)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Remote Monitoring Approaches to Reduce Readmissions After Infection and Sepsis

Posted June 9, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 10:30 A.M. ET, THURSDAY, JUNE 11, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16641?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: Among trial patients discharged after hospitalization for serious infections, remote monitoring did not increase time spent alive at home but reduced it in those 65 years and older. These findings support reevaluating and tailoring remote monitoring after acute care for sepsis and lower respiratory tract infection to support further alignment with patients’ needs and desire for personalized monitoring.

Corresponding Author: To contact the corresponding author, Sachin Yende, MD, MS, email yendes@upmc.edu.

(doi:10.1001/jamanetworkopen.2026.16641)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Gastric Residual Volume Assessment in Critically Ill Children

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:00 A.M. ET, FRIDAY, JUNE 12, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10639?guestAccessKey=46672cda-60df-49fb-8607-a7121c939aef&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061226

About The Study: Among critically ill children being enterally fed, not assessing gastric residual volume routinely was noninferior to regular assessments every 6 hours and significantly increased nutritional achievement at 72 hours.

Corresponding Author: To contact the corresponding author, Lyvonne N. Tume, PhD, email Lyvonne.tume@edgehill.ac.uk and l.n.tume@ljmu.ac.uk.

(doi:10.1001/jama.2026.10639)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Sodium Bicarbonate for In-Hospital Cardiac Arrest

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:00 A.M. ET, THURSDAY, JUNE 11, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10628?guestAccessKey=132e1adf-5bd2-4795-a28e-3f64dc34c7b6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061126

About The Study: There was no significant difference in sustained return of spontaneous circulation between sodium bicarbonate and placebo in adults with in-hospital cardiac arrest. These findings do not support routine administration of sodium bicarbonate for patients with in-hospital cardiac arrest.

Corresponding Author: To contact the corresponding author, Lars Wiuff Andersen, MD, MPH, PhD, DMSc, email lwandersen@clin.au.dk.

(doi:10.1001/jama.2026.10628)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Integrated Telehealth Rehabilitation and Quality of Life in Mechanically Ventilated Adults

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10:30 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10617?guestAccessKey=4fc4ae2c-711e-40d7-8c2d-653464b74aa6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: In this study, an integrated telehealth-based rehabilitation strategy delivered across intensive care unit, hospital, and postdischarge phases improved 90-day health-related quality of life, potentially influenced by reduced mortality.

Corresponding Author: To contact the corresponding author, Regis Goulart Rosa, MD, PhD, email regis.rosa@hmv.org.br.

(doi:10.1001/jama.2026.10617)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 8:30 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10616?guestAccessKey=9036397b-730b-4664-bd38-3ee4c5ca8e95&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: Among patients with severe burn injury, high-dose intravenous vitamin C did not reduce 28-day mortality and persistent organ dysfunction and is possibly harmful.

Corresponding Author: To contact the corresponding author, Christian Stoppe, MD, email christian.stoppe@gmail.com.

(doi:10.1001/jama.2026.10616)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Changes in Genetic Contributions to ASD and ADHD by Year of Diagnosis

Posted June 8, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1450?guestAccessKey=38a776c5-f92a-45e4-b74e-4f238a9ffdf7&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: By analyzing multiple polygenic scores together with simulated expectations, this study could disambiguate among competing hypotheses about scenarios that may be associated with increased rates of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) diagnoses. Findings support broadening diagnostic criteria as an explanation for increasing rates, with implications for understanding changes in risk factors and clinical practice.

Corresponding Authors: To contact the corresponding authors, email Sonja LaBianca, MD, PhD, (sonja.labianca@regionh.dk) and Andrew J. Schork, PhD, (Andrew.Joseph.Schork@regionh.dk).

(10.1001/jamapsychiatry.2026.1450)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia

Posted June 8, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1296?guestAccessKey=11f24b55-4e87-4918-ab66-bf4a155ce272&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: The convergent data in this study support a prospective clinical trial of low-dose lithium orotate to slow disease progression in mild cognitive impairment. Such an approach would prioritize established neuroprotective mechanisms while potentially mitigating the kidney and thyroid risks associated with higher-dose carbonate formulations. If low-dose lithium can indeed meaningfully alter disease trajectory, it would represent a much-needed, accessible, and inexpensive treatment that may be especially relevant in low- and middle-income countries.

Corresponding Author: To contact the corresponding author, Husseini K. Manji, MD, email husseini.manji@psych.ox.ac.uk.

(10.1001/jamapsychiatry.2026.1296)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Wearable Devices and Data Sharing in the US

Posted June 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17733?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this serial survey study, wearable device use increased among U.S. adults, but daily use and clinician-directed data sharing remained limited. These findings suggest that there is a need for approaches to help realize the potential of wearable devices as health care tools, both by broadening uptake and promoting consistent use.

Corresponding Author: To contact the corresponding author, Rohan Khera, MD, MS, email rohan.khera@yale.edu.

(doi:10.1001/jamanetworkopen.2026.17733)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Artificially Sweetened and Sugar-Sweetened Beverage Intake and Risk of Liver Cancer

Posted June 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17754?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this study, increased sugar-sweetened beverage consumption was associated with increased risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. There was little evidence that artificially sweetened beverage intake was associated with liver cancer risk overall or by subtype.

Corresponding Author: To contact the corresponding author, Katherine A. McGlynn, PhD, email mcglynnk@nih.gov.

(doi:10.1001/jamanetworkopen.2026.17754)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Acute Respiratory Tract Infections and Severe Disease Among Hospitalized Children

Posted June 5, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 9, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17575?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060926

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This cohort study found that hospitalized children with acute respiratory tract infections frequently have underlying chronic conditions and often require intensive intervention. Understanding the epidemiologic profile and factors associated with risk of severe disease in this population can inform resource allocation to optimize outcomes for pediatric patients.

Corresponding Author: To contact the corresponding author, Haifa Mtaweh, MD, PhD, email haifa.mtaweh@sickkids.ca.

(doi:10.1001/jamanetworkopen.2026.17575)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Large Language Model Chatbot Conversations vs Public Health Materials and Parental HPV Vaccination Intentions

Posted June 4, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16822?guestAccessKey=fd9934b0-bfd6-48b5-b121-d4ee7c77fda8&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060826

Corresponding Author: To contact the corresponding author, Neil K. R. Sehgal, ME, email Holly Wojcik at hwojcik@seas.upenn.edu.